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Abstract
Background: Restless Legs Syndrome is a very common disorder in hemodialysis patients. Restless Legs Syndrome
negatively affects quality of life; however it is not clear whether this is due to mental or physical parameters and whether an
association exists between the syndrome and parameters affecting survival.
Methodology/Principal Findings: Using the Restless Legs Syndrome criteria and the presence of Periodic Limb Movements
in Sleep (PLMS/h .15), 70 clinically stable hemodialysis patients were assessed and divided into the RLS (n=30) and non-
RLS (n=40) groups. Physical performance was evaluated by a battery of tests: body composition by dual energy X ray
absorptiometry, muscle size and composition by computer tomography, while depression symptoms, perception of sleep
quality and quality of life were assessed through validated questionnaires. In this cross sectional analysis, the RLS group
showed evidence of thigh muscle atrophy compared to the non-RLS group. Sleep quality and depression score were found
to be significantly impaired in the RLS group. The mental component of the quality of life questionnaire appeared
significantly diminished in the RLS group, reducing thus the overall quality of life score. In contrast, there were no significant
differences between groups in any of the physical performance tests, body and muscle composition.
Conclusions: The low level of quality of life reported by the HD patients with Restless Legs Syndrome seems to be due
mainly to mental health and sleep related aspects. Increased evidence of muscle atrophy is also observed in the RLS group
and possibly can be attributed to the lack of restorative sleep.
Citation: Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, et al. (2011) Evidence of Increased Muscle Atrophy and Impaired Quality of Life
Parameters in Patients with Uremic Restless Legs Syndrome. PLoS ONE 6(10): e25180. doi:10.1371/journal.pone.0025180
Editor: Ian Lanza, Mayo Clinic, United States of America
Received July 1, 2011; Accepted August 26, 2011; Published October 3, 2011
Copyright:  2011 Giannaki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the 03ED375 research grant, implemented within the framework of the ‘‘Reinforcement Programme of Human Research
Manpower’’ (ENTER) and co-financed by National and Community Funds (25% from the Greek Ministry of Development-General Secretariat of Research and
Technology and 75% from E.U. European Social Fund). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gsakkas@med.uth.gr
Introduction
Restless Legs Syndrome (RLS) is a sensory-motor neurological
disorder characterized by an irresistible urge to move one’s
extremities. This unpleasant sensation becomes worse during
inactivity and especially at night [1]. RLS is a very common
feature among patients receiving hemodialysis (HD) therapy [2–4]
and in this case it is called uremic RLS. In uremic patients, RLS
has been associated with poorer quality of life (QoL) compared to
RLS free patients [5–8], however it is not clear whether the
impaired QoL is due to physical or mental aspects of the QoL.
Reductions in physical performance and physical functioning,
and increasing restraints to independent living are affecting QoL
in HD population [9], whereas muscle wasting and low lean body
mass are additionally associated to lower survival rates [10,11]. It
has been reported that HD-RLS patients have a higher mortality
rate compared to their non RLS counterparts [8,12]. However, it
is still unknown whether HD patients with RLS experience any
further declines in parameters directly affecting survival such as
body composition, muscle quality and quantity, physical perfor-
mance and functional capacity, compared to RLS free patients.
The possible effect of RLS on these parameters is ambiguous.
On one hand, the discomfort that the syndrome induces to the
patients, may lead to avoidance and lack of exercise. On the other
hand, the repeated movement-relaxation cycle that the RLS
patients experience in order to get relief from the symptoms could
lead to a relatively increased physical activity. Nevertheless, both
scenarios could affect body composition as well as the quality and
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and morbidity rates.
Moreover, RLS, either in its idiopathic [13] or uremic [6] form,
is well known to impair patients’ sleep. Disturbed sleep is reported
to be associated with reductions in circulating anabolic hormones
[14,15] thus it could affect muscle metabolism. Indeed, some data
indicates that the lack of sleep is associated with reduced muscle
size in HD patients [16] and it is plausible that in HD patients with
RLS the anabolic effect of sleep might be further reduced. Given
that RLS disturbs sleep quality, we hypothesized that this could
have a detrimental effect in the HD patient’s muscle quantity and/
or quality.
Given the high prevalence of undiagnosed RLS in HD
patients,[5,17] and the fact that RLS by nature could influence
aspects of physical performance, physical functioning and QoL,
such as endurance, body composition and muscle size, it is
conceivable to assume that research outcomes based on HD
populations could have been confounded in the past.
The aims of the present study were to investigate whether HD
patients with RLS, as compared to those without the syndrome,
show evidence of further reduced quality of life and of overall
physical performance and functional capacity, as well as further
alterations in indices of body composition and muscle character-
istics, parameters that could have a significant impact in the
survival and quality of life in this patient- population.
Methods
Ethics Statement
The study was approved by the Ethics Committee of the
University of Thessaly, and by the bioethics committee of the
University General Hospital of Larissa, Greece and the bioethics
committee of the General Hospital of Trikala, Greece. All patients
gave their written informed consent prior to study participation.
Study Population
From September of 2006 to July of 2010, a total of eighty-five
HD patients (the total number of patients receiving care in the
study centers) were screened while seventy HD patients (51 male,
19 female, 54.1616.9 years) were finally enrolled in the study
(Figure 1). The patients were recruited from the HD units of the
University Hospital of Larisa (UHL) and from the General
Hospital of Trikala, Greece.
The inclusion criteria for the study were: dialysis for at least
three months or more with adequate dialysis delivery and with
stable clinical condition. In addition, none of the recruited patients
should have been diagnosed with RLS prior to the study.
Exclusion criteria included diagnosed neuropathies (n=8, clini-
cally examined by a neurologist) or reasons for being in a catabolic
state (n=4, including malignancies, opportunistic infections or
active inflammation), within 3 months prior to the start of the
study, or with abnormal C-Reactive Protein blood levels. In
addition, another 3 patients refused to participate to the study for
personal reasons.
Allocation
Patients were divided into two groups according to their RLS
status: the RLS group (n=30; 10 females, 55.4613.4 years) and
the non-RLS group (n=40; 9 females, 53.1619.3 years).
RLS diagnosis and severity assessment
RLS was diagnosed by a single RLS specialist neurologist, using
the internationally recognised criteria of the IRLSSG [1], whereas
the presence of Periodic Limb Movements in Sleep (PLMS) was
derived from an overnight polysomnographic (PSG) study
(Somnoscreen, Somnomedics GmbH, Randersacker, Germany).
According the International RLS Study Group, the presence of
PLMS is considered as a supportive and not conclusive clinical
feature for the diagnosis of the syndrome and therefore it was used
complementary to the IRLSSG criteria [1]. The assessment of
PLMS was performed according to the official World Association
of Sleep Medicine standards for recording and scoring of PLMS
with a cut off threshold at .15 events per hour [18]. RLS patients
were included in the study if they had at least one RLS episode per
week excluding the episodes that took place during the dialysis
session. Finally, RLS severity was assessed using the IRLSSG
severity rating scale [19].
Study design
This is a cross sectional study. Patients screening for RLS took place
prior to any measurements and the status of the patients was coded for
blinding purposes. All investigators were blinded to the RLS status of
the patients up to the completion of data analysis. Patients were studied
in a single out-patients visit on a free dialysis day.
Body and muscle composition
A DEXA system (Lunar model DPX Madison, WI) was used to
measure the patient’s whole body fat and lean body mass [20].
Post-hoc regional analysis of the DEXA images was performed as
described previously [21]. In addition, muscle size and composi-
tion of the right thigh was assessed by computed tomography (CT)
(Philips Tomoscan SR5000) [22] with image analysis performed as
previously described [16]. Waist to hip ratio (WHR) was
calculated as waist circumference, at the midway between the
iliac crest and the lowermost margins of the ribs, over the hip
circumference at the maximum circumference of buttocks.
Physical performance assessment
Patients’ physical performance was evaluated by a battery of
tests. Briefly, we used the ‘‘North Staffordshire Royal Infirmary’’
walking test (NSRI), two gait speed tests (normal and fast walk
tests) and two sit-to-stand tests (STS-5 and STS-60) as previously
described [23–25].
Questionnaires
All questionnaires were completed with the interview method,
by experienced personnel. The patient’s subjective QoL outcomes
were evaluated by using a Short Form-36 Health Survey (SF-36)
version modified for patients receiving HD therapy [26]. Outcome
scores can range from 0 to 100, with higher scores indicate better
health status. The 8 multi-item scales of the SF-36 were
summarized into two dimensions (mental and physical dimension
respectively) and into a ‘‘total or overall SF-36 score’’ [26]. The
patient’s score in the physical health component was considered as
the ‘‘physical functioning’’ score [27,28].
The patients’ depression levels were evaluated by using a 20-
item self-rating depression scale questionnaire developed by Zung
[29], used successfully in the past in HD patients [16,30]. The cut-
off point for the diagnosis of clinical depression is above 50.
The Epworth sleepiness scale (ESS) was used to assess the daily
sleepiness level of the patients [31]. ESS consists of questions
referring to eight situations. The patients are asked to rate on a
scale of 0 up to 3 how likely they would be to doze off or fall asleep
during the 8 situations. Outcome scores can range from 0 to 24. A
score above 10 is considered to be pathological sleepiness.
A weekly sleep diary, adapted from the University of Massachu-
setts Medical School website (http://healthnet.umassmed.edu/
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patient’s quality of sleep. Briefly, the sleep diary contained questions
regarding how often during the previous week HD patients
experienced any of the following: (1) difficulties falling asleep, (2)
number of nocturnal awakenings, (3) difficulties remaining asleep,
(4) the sensation of waking-up tired and fatigued, (5) day time stress
and (6) how often did they feel refreshed after the night’s sleep. The
sleep diary was scored as follows: ‘never’ (0 points), ‘1–2 times a
week’ (1 point), ‘3–5 times a week’ (2 points), ‘6–7 times a week’ (3
points). For question number 6 the scoring was reversed with 3
points for the answer ‘never’, and 0 points for the answer ‘6–7 times
a week’. The sleep diary score was calculated as the sum of the total
points with the minimum at zero points and the maximum score at
18.]
Nutritional assessment
The nutritional status of the patients was examined by the
Subjective Global Assessment (SGA) method [32].
Biochemical assessment
Routine monthly laboratory results were recorded for HD
subjects including ferritin, hematocrit, hemoglobin and dialysis
efficiency parameters. A single-pool Kt/V was calculated from
pre- and post-dialysis BUN measurements using the Daugirdas II
equation [33]. The biochemical analysis was performed at the
clinical lab of the UHL under standard hospital procedures.
Hemodialysis procedure
Patients underwent HD therapy (Fresenius 4008B, Oberursel,
Germany) for at least 4 hours, 3 times/week, with hollow-fiber
dialysers and bicarbonate buffer. Low molecular weight heparin
(Enoxaparin, ClexaneH, Sanofi-Aventis, Strasbourg, France) was
applied for anticoagulation. Enoxaparin doses of 40–60 mg were
administered intravenously before the beginning of HD treatment.
EPO therapy was given after the completion of HD session in
order to normalize hemoglobin within 11-12 (g/dL).
Statistical analysis
For the patients’ characteristics (Table 1) an unpaired t-test were
used to compare groups for continuous normally distributed
variables; chi-square, for categorical variables; and Mann-Whitney
U test, for non–normally distributed variables. Multivariate
Analysis of covariance (MANCOVA) with ‘‘gender’’ as a
covariance was used in order to control for possible differences
between the examined variables (Tables 2–3). Spearman rank
correlation test was used to assess the relationships between the
examined variables, while for correlation between continuous and
categorical variables a ‘‘Point Biserial Correlation Coefficient’’ test
was used to assess this type of relationship. All analyses were
carried out using the SPSS Statistical Package (SPSS 15.0,
Chicago, Illinois). Data are presented as mean 6 SD unless
otherwise stated and the level for statistical significance was set at
P,0.05.
Sample Size
Sample size calculations were conducted based in functional
capacity [NSRI 73.5(30) vs 105(37)] and quality of life score
[78.1(12.9) vs 63.7(20.2)] values in the hemodialysis patients from
previous published articles [16,34]. The resulting minimum
required sample size was an average of 30 for 2-sided type 1
and type 2 errors of 5%.
Results
In this cross sectional analysis, the prevalence of RLS within the
HD population was approximately 42% (30 out of 70), whereas
57% of those (17 out of 30) co-experienced PLMS. The RLS
patient’s score in the IRLS severity scale was 2469, which
categorized them at the ‘‘severe’’ level of symptoms’ intensity.
The prevalence of RLS was found to be higher in women
compared to men (52% vs 39%), however no gender effect was
observed in the current analysis (P=0.313).
The patients’ characteristics are presented in Table 1 and
physical performance data are presented in Table 2. There were
Figure 1. Patient recruitment flow diagram. Disposition of the patients into the two groups according to the RLS diagnosis as follows: the RLS
group and the non-RLS group.
doi:10.1371/journal.pone.0025180.g001
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physical performance tests performed. In contrast, significant
differences were found in the QoL assessment results (Figure 2), in
the sleep diary [F (1,60)=8.472, P=0.005], in the severity of the
Zung self-rating depression scale [F (1,60)=6,922, P=0.011] and
a trend in the sleepiness scale [F (1,60)=3,656, P=0.060]
(Table 2).
The severity of RLS symptoms ‘score (IRLS) was correlated
significantly with the score in sleep diary (r=0.410, P=0.030).
The prevalence of RLS was correlated with sleep diary
(rpb=+0.31, P=0.01), and Zung depression scale scores
(rpb=+0.29, P=0.01), whereas significant negative correlations
were found between the IRLS score and the overall score of the
SF-36 (r=2.0423, P=0.022).
Total body composition assessment did not show any differences
between the two groups. The CT analysis showed that the thigh
muscle total area, muscle cross sectional area (CSA) and the level
of muscle fat infiltration (EMCL-extramyocellular lipids) were
significantly reduced in the RLS group (Table 3). In addition,
muscle CSA/total LBM ratio and EMCL CSA/total body fat
ratio were found to be significantly increased in the non-RLS
group [F (1,41)=7.538, P=0.009] and [F (1,41)=4.130,
P=0.048] respectively, whereas, no significant differences were
found in the percentage of muscle and EMCL between the two
groups [F(1,41)=2.207, P=0.145].
Discussion
A 42 % of the examined patients were diagnosed with RLS in
agreement with other recent studies [35]. To the best of our
knowledge this is the first study assessing parameters that affect
survival and quality of life in such detail in patients with uremic
RLS. We found that the size of proximal muscles was significantly
reduced in the RLS group, however, uremic RLS did not seem to
have an additional detrimental impact on the already diminished
physical performance, body and muscle composition and physical
aspects of the quality of life in HD patients. The low level of QoL
reported by the RLS- HD patients seems to be due mainly to
mental health and sleep related aspects rather than the physical
aspects.
It is well known that HD patients are characterized by low VO2
peak,[9] reduced physical performance, high levels of weakness
and exercise intolerance [36]. In the RLS population with normal
kidney function, maximal oxygen uptake values [37] and physical
fitness levels [38] have been found to be lower compared to non-
RLS healthy individuals. It is, therefore, plausible to hypothesize
that HD patients with RLS could have been affected in an additive
or synergistic way by uremia and RLS, and that this combination
would affect their functional capacity and physical performance.
In the current study patients of both groups responded similarly in
all physical performance tests, implying that there was no
discernible effect of RLS on physical performance in patients
receiving dialysis therapy. In agreement to our findings, a study
that assessed elderly idiopathic RLS patients using the same
methodology with us, found no significant differences in physical
performance between sufferers and non-sufferers [39].
Moreover, it is known that HD patients are characterized by
significant reductions in muscle size and increased muscle fat
infiltration [40]. The analysis of CT images revealed among other
that the total thigh area was reduced by 15%, the muscle CSA by
17% and the EMCL CSA area by 38% in the RLS-HD patients.
This reduction of muscle mass is worrisome especially since muscle
atrophy is usually prominent in HD patients and has been related
to high mortality [11]. Independently from the increased levels of
atrophy however, there were no visible changes in the muscle
composition between groups and this could be speculated to be a
positive counteracting effect induced by the increased muscle
activity in which RLS patients involuntarily engage. The reduction
of total thigh muscle area in the RLS group could be partially
explained by the respective reductions in both EMCL and muscle
CSAs that were found in that group and not by the amount of
subcutaneous fat tissue as this appeared to be similar in both
groups.
Table 1. Patient’s characteristics presented as pool data and
divided in two groups according to RLS diagnosis.
Variables
Patients
Pool Data Non RLS RLS P values
N 7 04 03 0 -
Female / Male 19/51 9/31 10/20 0.313
¥
Age (yr) 54.1616.9 53.1619.3 55.4613.4 0.580
BMI (Kg/m
2) 25.564.2 25.264.5 25.863.9 0.580
Kt/V 1.2460.4 1.2560.5 1.2260.4 0.802
Years in Hemodialysis 3.062.6 2.561.6 3.763.5 0.093
WHR 0.9760.07 0.9760.06 0.9760.07 0.744
PLMS prevalence 26 (37%) 9 (22%) 17 (57%) 0.008
¥
PLMS index (per hour) 20.4629.3 10.3620.2 31.5633.7 0.003
IRLS score - - 23.7 6 9.2 -
SGA (A/B/C) 31/9/1 22/7/1 9/2/0 0.820
¥
Ferritin (ng/ml) 202.36189.5 173.26173.3 241.16206.6 0.187
Hct 36.364.9 35.765.5 37.063.9 0.300
Hb (g/dL) 11.861.6 11.561.6 12.261.5 0.107
All data are mean 6 SD. Abbreviations: BMI, body mass index; Kt/V, dialysis
efficiency; WHR, waist to hip ratio; PLMS, Periodic Limb Movements in Sleep;
IRLS, International Restless Legs Syndrome severity scale; SGA, subjective global
assessment; Hct, hematocrit; Hb, hemoglobin.
¥For categorical data a chi-square test was performed.
doi:10.1371/journal.pone.0025180.t001
Table 2. Physical performance, depression, daytime
sleepiness and sleep quality data.
Variables
Patients
Pool Data Non RLS RLS P values
Physical Performance Tests
STS- 5 (sec) 10.162.8 10.463.3 9.761.9 0.330
STS-60 (rep) 27.868.4 28.868.9 26.667.6 0.339
Normal Walk (sec) 5.961.4 5.961.5 5.861.2 0.572
Fast Walk (sec) 4.161.0 4.161.1 4.160.9 0.687
NSRI test (sec) 84.3636.8 85.6641.4 82.7630.5 0.503
Questionnaires
Sleep Diary 7.264.8 5.764.3 9.264.7 0.005
Epworth Sleepiness
Scale
6.164.1 5.363.7 7.164.4 0.060
Zung Depression Scale 41.069.6 38.268.3 44.4610.1 0.011
All data are mean 6 SD. P values are adjusted for yrs in dialysis. Abbreviations:
STS-5, sit-to- stand test 5-repetitions; STS-60, sit-to- stand test 60 seconds; NSRI,
North Staffordshire royal infirmary test.
doi:10.1371/journal.pone.0025180.t002
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a result of an increased fat oxidation due to higher muscle activity,
as it is observed in highly trained athletes [41] however this is only
a hypothesis and it should be seen with caution. The fact that no-
significant differences were observed in the nutritional status
within the two groups, could indicate that the observed differences
in the HD-RLS patient’s muscle size were not caused by
malnutrition. Overall, it seems that the observed changes in
muscle size do not have the magnitude to worsen functionality and
further reduce physical activity in HD patients with RLS.
Table 3. Body composition data.
Variables Patients Pool Data Non RLS RLS P values
DEXA Body Composition Analysis
Total Body Fat (%) 27.4611.3 25.3611.9 29.7610.5 0.554
Trunk Fat (%) 27.9611.3 26.1612.3 29.969.7 0.559
% Legs Fat 27.4611.2 25.0612.2 30.0611.9 0.515
% Arms Fat 24.4612.6 22.3612.7 26.6612.3 0.744
Total LBM (Kg) 46.168.8 47.369.2 44.968.3 0.985
Legs LBM (kg) 14.563.1 15.263.4 13.863.7 0.333
Arms LBM (kg) 5.061.4 5.561.6 4.661.0 0.091
CT Thigh Analysis
Thigh Total Area (cm
2) 112.1625.5 119.4628.9 104.3618.8 0.050
EMCL CSA (cm
2) 17.468.7 20.168.6 14.568.0 0.022
EMCL CSA/Total Body Fat 1.161.2 1.661.7 0.760.4 0.048
EMCL (%) 15.767.4 17.266.8 14.167.7 0.089
Muscle CSA (cm
2) 94.5625.2 101.4628.8 87.1618.4 0.066
Muscle CSA/Total LBM 2.160.4 2.260.4 1.960.3 0.009
Muscle (%) 82.766.9 82.466.8 83.167.2 0.187
Muscle (%)/EMCL (%) 7.465.3 6.363.1 8.466.7 0.145
SAT CSA (cm
2) 115.0654.1 113.5656.7 116.5652.5 0.723
All data are mean 6 SD. P values are adjusted for yrs in dialysis. Abbreviations: LBM, lean body mass; EMCL, extramyocellular lipids (fat infiltration); CSA, cross sectional
area; SAT, subcutaneous adipose tissue.
doi:10.1371/journal.pone.0025180.t003
Figure 2. Health-related Quality of Life scores for the RLS (in black) and non-RLS (white bars) hemodialysis patients. Vertical line: The
first two sets of bars on the right of the vertical bar are the summary physical and mental dimension score while the last set of bars at the far right is
the total SF-36 score.
doi:10.1371/journal.pone.0025180.g002
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turn could evoke alterations in anabolic hormones secretion and
circulation such as in growth hormone (GH) and insulin-like
growth factor I (IGF-I) [14,15] eventually affecting the patient’s
anabolism and muscle mass. Subjective sleep quality was found
reduced by 61% (sleep diary) reinforcing the hypothesis that the
lack of restorative sleep could be one of the factors affecting muscle
mass. The RLS-induced sleep deprivation is an important health
issue that needs to be addressed further in order to reduce all the
possible factors contributing to muscle atrophy and accelerated
catabolism in HD patients.
Depression symptoms are common in patients receiving HD
therapy [42,43]. It is plausible that HD patients with RLS might
experience higher levels of depression as a result of their restless
night,therelatedinsomniaand theoverallreduced QoLthat RLSis
associated with [44]. Indeed, the RLS group showed higher
depression score than the non-RLS group confirming previous data
[45,46], and the RLS status significantly correlated with the score in
the Zung depression scale. Even thought depression score was
elevated in both groups, none of them exceeded the threshold for
the diagnosisof clinical depression (cutoff,50). It is also known that
low sleep quality exacerbates the severity of depression symptoms
seen in HD patients [47] and this is in agreement with our findings.
Given that the sleep quality in the HD patients with RLS is
significantly impaired compared to the HD patients without the
syndrome[5], thiscould explain inpart thedifferences indepression
symptoms severity score between the two groups. This also agrees
with our PLMS results, as PLMS were two fold increased in the
RLS HD patients affecting even more their sleeping pattern.
So far it was not clear whether the impaired QoL seen in RLS
HD patients was due to physical or mental QoL components. A
closer look at the questionnaires as well as the physical
performance tests reveals that the differences between the two
groups are better explained by their diminished mental rather than
their physical aspects, confirming data derived from previous
studies in RLS in HD patients [5,6]. To the best of our knowledge
ours is the first study to carefully investigate, by using both indirect
(surveys-questionnaires) and direct (physical performance tests)
approaches, what quality of life aspects are the most affected in
these patients. The revealed consequences seem to be common
also for other symptomatic forms of the sleep disorder (e.g. RLS
due to type 2 diabetes). In the past, Merlino et al. concluded that
patients accustomed to severe physical dysfunctions (eg, uremia
and diabetes) complain of RLS more as a mental distress than a
physical one [48] without however providing measurable indices
(e.g. functional tests) of the presence or lack of physical
impairments. The current study reports a higher level of
depression and even poorer sleep quality in the HD patients with
RLS compared to their RLS-free counterparts.
RLS severity has been associated with lower survival [8] while
PLMS severity is considered an independent predictor of mortality
[49]. In the current study, the intensity of the syndrome in our
RLS patients was categorized as ‘‘severe’’ [19] implying that those
patients might be subjects to a higher CVD risk. However, such a
claim will have to be further validated, as it was not
straightforward substantiated by our findings.
Limitations
It has been reported that PLMS index can vary across nights in
patients with idiopathic RLS [50] but it is not known if the same
phenomenon exists in patients with secondary type of RLS. Thus,
in that respect our data should be viewed with caution since the
PLMS indices obtained by a single overnight PSG study may be
not as reliable as if we had used an average of two or even three
consecutive assessment nights.
In conclusion, hemodialysis patients with RLS reported lower
quality of life and overall scored worse in mental rather than
physical parameters compared to their RLS free counterparts. The
size of proximal muscles was found to be significantly reduced in
the RLS group, however, uremic RLS did not seem to have an
additional detrimental impact on the already diminished physical
performance, body and muscle composition and physical aspects
of the quality of life in HD patients. It is possible that the potential
negative impact of RLS on the above parameters could have been
masked under the dominant impact of uremia and/or hemodial-
ysis per se. Screening for RLS should be part of the routine general
health assessment of the hemodialysis patients as it affects QoL
and possibly overall health status.
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